PGV002

PGV002 is a **personalized neoantigen mRNA cancer vaccine** developed by NeoCura for the treatment of solid tumors and other cancers. As an individualized immunotherapy, PGV002 encodes tumor-specific neoantigens identified from a patient’s cancer, delivered via mRNA to stimulate a targeted immune response against cancer cells. Its main therapeutic aim is to activate and enhance anti-tumor immunity through patient-specific immunostimulation, potentially in both monotherapy and combination therapy settings. The vaccine is administered parenterally and is in the clinical development stage, with initial clinical activity planned in adult patients with solid tumors[1][5][8].

Other names

PGV002 mRNA vaccinePGV-002 mRNA vaccinePGV 002 mRNA vaccinePersonalized neoantigen tumor vaccine NeoCura